Our study enrolled more homogenous patients without any prior anti-tumor therapy and mainly focused on the efficacy of the PD-1 monoclonal antibody inhibitor plus lenvatinib in stage IV GBC. This evidence concerns the gene PDCD1 and neoplasm.